The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (ALLIANCE).
Jai Narendra Patel
No relevant relationships to disclose
Chen Jiang
No relevant relationships to disclose
Daniel Louis Hertz
No relevant relationships to disclose
Flora Mulkey
No relevant relationships to disclose
Paula N. Friedman
No relevant relationships to disclose
Susan Halabi
No relevant relationships to disclose
Mark J. Ratain
No relevant relationships to disclose
Michael J. Morris
No relevant relationships to disclose
Eric Jay Small
No relevant relationships to disclose
Kouros Owzar
No relevant relationships to disclose
William Kevin Kelly
No relevant relationships to disclose
Howard L. McLeod
No relevant relationships to disclose